TIDMMXCT TIDMTTM
RNS Number : 3628U
MaxCyte, Inc.
28 March 2023
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
Rockville, MD, March 28, 2023 - MaxCyte, Inc. , (Nasdaq: MXCT;
LSE: MXCT), a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell-based
therapeutics and to support innovative, cell-based research, today
announced Douglas J. Swirsky has been appointed as the Company's
Chief Financial Officer, effective immediately. Mr. Swirsky is a
seasoned financial leader with over two decades of experience in
the healthcare sector, including as a public company executive at
Nasdaq-listed organizations.
" We are excited to welcome Douglas to MaxCyte where he brings
exceptional financial, strategic, and operational experience in the
life science and biopharmaceutical sectors, including extensive
experience as a public company CFO," said Doug Doerfler, President
and CEO of MaxCyte. "His breadth of experience will play a pivotal
role in MaxCyte's continued growth as an industry leading
cell-engineering company. We look forward to leveraging his deep
finance and industry knowledge as we execute on our strategic and
financial goals."
Prior to joining MaxCyte, Mr. Swirsky served as Chief Financial
Officer and Treasurer of AavantiBio, Inc. a gene therapy company,
from February 2021 until its acquisition by Solid Biosciences, Inc
. in December 2022, initially joining AavantiBio as its Interim
President and a director in May 2020. Mr. Swirsky's experience also
includes serving as President, Chief Executive Officer and a
director of Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) from 2018
to 2020. Mr. Swirsky served as President, CEO and a director of
GenVec, Inc. (NASDAQ: GNVC), a publicly traded biotechnology
company, a position he held from 2013 through the sale of the
company in 2017. He joined GenVec in 2006 as Chief Financial
Officer.
Prior to GenVec, Mr. Swirsky was a Managing Director and the
Head of Life Sciences Investment Banking at Stifel Nicolaus and
previously held investment banking positions at Morgan Stanley,
UBS, PaineWebber, and Legg Mason. Mr. Swirsky currently serves as
the Chairman of the Board of Cellectar Biosciences, Inc. (NASDAQ:
CLRB), a publicly traded clinical stage biopharmaceutical
company.
Mr. Swirsky is a certified public accountant and a CFA(R)
charterholder. He received his B.S. in Business Administration from
Boston University and his M.B.A. from the Kellogg School of
Management at Northwestern University.
"I am honored to join MaxCyte's strong leadership team during
this exciting period of growth at the Company, and to support our
mission to help drive the next generation of cell-based therapies,"
said Douglas Swirsky. "As CFO, I look forward to leading MaxCyte's
financial operations to position the Company for continued success,
and to helping create long term shareholder value."
Ron Holtz, who served as MaxCyte's CFO from 2005 until September
2020 and again since May 2022, having served as Chief Accounting
Officer during the interim period, will take on the role of EVP,
Administration for the Company.
"It has been an honor serving as part of the MaxCyte executive
team for nearly eighteen years," said Ron Holtz. "I welcome Douglas
to MaxCyte and look forward to supporting his success as MaxCyte's
CFO. His exceptional background and experience will be invaluable
to MaxCyte as we move forward through the next phases of
growth."
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation (R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn .
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including but not limited
to, statements regarding the Company's expected growth and its
execution of its strategic and financial goals. The words "may,"
"might," "will," "could," "would," "should," "expect," "plan,"
"anticipate," "intend," "believe," "expect," "estimate," "seek,"
"predict," "future," "project," "potential," "continue," "target"
and similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements in this press release are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, risks associated with the timing of
our customers' ongoing and planned clinical trials; the adequacy of
our cash resources and availability of financing on commercially
reasonable terms; general market and economic conditions that may
impact investor confidence in the biopharmaceutical industry and
affect the amount of capital such investors provide to our current
and potential partners; and demand for our products. These and
other risks and uncertainties are described in greater detail in
the section entitled "Risk Factors" in our Annual Report on Form
10-K for the year ended December 31, 2022, filed with the
Securities and Exchange Commission on March 15, 2023, as well as in
discussions of potential risks, uncertainties, and other important
factors in the other filings that we make with the Securities and
Exchange Commission from time to time. These documents are
available under the "SEC filings" page of the Investors section of
our website at http://investors.maxcyte.com . Any forward-looking
statements represent our views only as of the date of this press
release and should not be relied upon as representing our views as
of any subsequent date. We explicitly disclaim any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOANKOBQPBKDCNB
(END) Dow Jones Newswires
March 28, 2023 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024